This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Efficacy and safety of the dopaminergic stabilizer Pridopidine (ACR16) in patients with Huntington’s disease


Lundin, Anders, Dietrichs, Espen, Haghighi, Sara, Göller, Marie-Louise, Heiberg, Arvid, Loutfi, Ghada, Widner, Håkan, Wiktorin, Klas, Wiklund, Leif, Svenningsson, Anders, Sonesson, Clas, Waters, Nicholas, Waters, Susanna, Tedroff, Joakim


Clinical Neuropharmacology, Volume: 33, No.: 5, Pages.: 260-264

Year of Publication



Objectives: To evaluate the efficacy and safety of the dopaminergic stabilizer pridopidine (ACR16) in patients with Huntington’s disease (HD).; Methods: In a randomized, double-blind, placebo-controlled, 4-week trial, patients with HD received pridopidine (50 mg/d, n = 28) or placebo (n = 30). The primary outcome measure was the change from baseline in weighted cognitive score, assessed by cognitive tests (Symbol Digit Modalities, verbal fluency, and Stroop tests). Secondary outcome measures included changes in the Unified Huntington’s Disease Rating Scale, Hospital Anxiety and Depression Scale, Leeds Sleep Evaluation Questionnaire, Reitan Trail-Making Test A, and Clinical Global Impression of Change. Safety assessments were also performed.; Results: There was no significant difference between pridopidine and placebo in the change from baseline of the weighted cognitive score. However, secondary measures such as affective symptoms showed trends toward improvement, and there was significant improvement in voluntary motor symptoms compared with placebo (P < 0.05). Pridopidine was well tolerated, with a safety profile similar to placebo.; Conclusions: Pridopidine shows promise as a treatment for some of the symptoms of HD. In this small-scale study, the most notable effect was improvement in voluntary motor symptoms. Larger, longer-term trials are warranted.;

Bibtex Citation

@article{Lundin_2010, doi = {10.1097/wnf.0b013e3181ebb285}, url = {}, year = 2010, month = {sep}, publisher = {Ovid Technologies (Wolters Kluwer Health)}, volume = {33}, number = {5}, pages = {260--264}, author = {Anders Lundin and Espen Dietrichs and Sara Haghighi and Marie-Louise Göller and Arvid Heiberg and Ghada Loutfi and H{aa}kan Widner and Klas Wiktorin and Leif Wiklund and Anders Svenningsson and Clas Sonesson and Nicholas Waters and Susanna Waters and Joakim Tedroff}, title = {Efficacy and Safety of the Dopaminergic Stabilizer Pridopidine ({ACR}16) in Patients With Huntington{textquotesingle}s Disease}, journal = {Clinical Neuropharmacology} }


acr16, affective symptoms, antagonists inhibitors, anxiety, cognition, dopamine, dopamine antagonists, dopaminergic, double-blind method, drug effects, drug therapy, female, humans, huntington disease, male, metabolism, middle aged, physiology, piperidines, pridopidine, psychology, receptors dopamine d2, severity of illness index, sleep, stabilizer, therapeutic use, treatment outcome

Countries of Study


Types of Dementia


Types of Study

Randomised Controlled Trial

Type of Outcomes

Cognition, Depression and Anxiety, Other

Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions